机构投资者 Marshall Wace 减持 Exelixis 股份，公司未达到盈利预期。 Institutional investor Marshall Wace reduced Exelixis holdings, company missed earnings estimates.

第四季度,机构投资者Marshall Wace LLP将其在生物技术公司Exelixis的股份减少了9.7%,出售了36 327股,现在拥有338 284股,价值11 265 000美元。 Institutional investor Marshall Wace LLP reduced its holdings in biotech firm Exelixis by 9.7% in the fourth quarter, selling 36,327 shares and now owning 338,284 shares worth $11,265,000. Exlixis报告季度EPS为0.48美元,缺失估计数为0.03美元。 Exelixis reported a quarterly EPS of $0.48, missing estimates by $0.03. 该公司的市场上限为99.6亿美元,分析师的平均价格目标为37.59美元,一致评为“Moderate Buy”。 The company has a market cap of $9.96 billion and an average analyst price target of $37.59, with a consensus rating of "Moderate Buy."